Collegium to acquire Ironshore Therapeutics for $550m.

Collegium, a specialty pharmaceutical company, agreed to acquire Ironshore Therapeutics, a pharmaceutical company that markets and distributes Jornay PM, for $550m. “The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and exclusivity into the 2030s. The addition of Jornay PM will establish a new presence for Collegium in ADHD, a large and growing market, where we can leverage our core commercial competencies and proven commercial execution capabilities to maximize the brand’s potential. Our healthy balance sheet and strong financial position enabled us to secure attractive financing for the transaction with terms that reduce our cost of capital and enhance our flexibility in the management of our debt," Michael Heffernan, Collegium Chairman and Interim President and CEO.